Breakthrough in Gene Therapy Stabilizes Neuropathy in Rare Nerve Disease
A groundbreaking gene editing therapy shows promise in stabilizing neuropathy symptoms and reducing disease markers in hereditary transthyretin amyloidosis, offering hope for long-term disease management.
Researchers from University College London's National Amyloidosis Center have reported promising results from a novel gene editing therapy for hereditary transthyretin amyloidosis with polyneuropathy, a serious and often fatal nerve disorder. The therapy, named nexiguran ziclumeran, involves a single infusion that significantly lowers serum transthyretin (TTR) protein levels. TTR is responsible for amyloid deposits in tissues, which cause nerve and organ damage.
In a multinational Phase I trial involving 36 patients across France, New Zealand, Sweden, and the UK, the treatment resulted in rapid, profound, and sustained reductions in TTR levels — a decrease of approximately 90% at 28 days and over 92% at 24 months. Notably, most patients' neuropathy scores remained stable or improved over the 24-month period, indicating a potential halt or slowdown in disease progression.
Hereditary transthyretin amyloidosis is characterized by the abnormal accumulation of misfolded TTR protein in peripheral nerves, leading to progressive nerve damage. The disease's median survival ranges from six to twelve years after onset, with current available treatments requiring ongoing administration and only partial efficacy.
This study, published in The New England Journal of Medicine, highlights the possible of gene editing to produce durable disease modification. The therapy was generally well-tolerated, with side effects mostly related to infusion reactions, headaches, diarrhea, and some changes in thyroid hormone levels. Serious adverse events included one death due to cardiac amyloidosis.
The findings suggest that a one-time gene editing approach like nexiguran ziclumeran could revolutionize the treatment landscape for this devastating disease, leading to more effective and less burdensome management options. Further research is ongoing to confirm long-term safety and efficacy.
Source: https://medicalxpress.com/news/2025-10-stabilization-neuropathy-scores-gene-therapy.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
AI Technology Aims to Detect Early Voice Box Cancer Through Voice Analysis
Emerging AI research demonstrates the potential to detect early voice box cancer through voice recordings, offering a non-invasive screening method that could revolutionize early diagnosis and improve survival rates.
Reduced Frequency of Stroke Monitoring Proven Safe and Resource-Efficient in New Study
A groundbreaking study reveals that reducing post-thrombolysis stroke monitoring frequency is safe, effective, and helps optimize healthcare resources, especially in resource-limited settings.
How Daylight Enhances the Immune System's Infection-Fighting Power
Discover how exposure to natural daylight can enhance your immune system's ability to fight infections by regulating neutrophil activity through circadian rhythms.
Despite Legal Protections, Many Physical Clinics Are Closing Across the U.S.
Many brick-and-mortar abortion clinics are closing across the U.S., driven by financial challenges despite legal protections, impacting access to reproductive healthcare especially in rural areas.